Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma

International Journal of Urology

Volumn 16, Issue 6, 2009, Pages 576-579

  Soga, Norihito ^a   Yamada, Yasushi ^a   Nishikawa, Kouhei ^a   Hasegawa, Yoshihiro ^a   Kise, Hideaki ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced renal cell carcinoma; Gemcitabine and capecitabine; Immunotherapy failure

Indexed keywords

CAPECITABINE; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; JAPANESE; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 66949127958     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02308.x     Document Type: Article

References (10)

1. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur. Urol. 2005 48 : 77 81. (Pubitemid 40835595)
2. Swanson DA. Surgery for metastases of renal cell carcinoma. Scand. J. Surg. 2004 93 : 150 5.
3. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006 24 : 16 24. (Pubitemid 46630489)
4. Waters JS, Moss C, Pyle L et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br. J. Cancer 2004 91 : 1763 8.
5. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000 92 : 205 16.
6. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2004 22 : 454 63.
7. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 2005 103 : 553 8.
8. Stadler WM, Halabi S, Rini B et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 2006 107 : 1273 9.
9. Kobayashi M, Nakano K, Ikeda H et al. A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy Gan To Kagaku Ryoho 2008 35 : 277 9 (in Japanese).
10. Tannir NM, Thall PF, Ng CS et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J. Urol. 2008 180 : 867 72.